Acquiring Company
Eli Lilly and Company
Acquired Company
Sigilon
IndianapolisManufacturingBiotechnologyHealth CareMedicalPharmaceuticalBiotechnologyHealth CareDescription
Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.
Who to call at Eli Lilly and Company, and when
When Eli Lilly and Company changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Eli Lilly and Company raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Eli Lilly and Company, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Eli Lilly and Company. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Eli Lilly and Company makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Sigilon?
Sigilon was acquired by Eli Lilly and Company, based in Indianapolis. The deal was reported on June 29, 2023. Lilly is a medicine company turning science into healing to make life better for people around the world. Eli Lilly and Company is publicly traded (LLY) and operates in Manufacturing.
When did Eli Lilly and Company acquire Sigilon?
Eli Lilly and Company's acquisition of Sigilon was reported on June 29, 2023. Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sigilon do?
Sigilon Therapeutics seeks to develop functional cures for patients with a broad range of acute and chronic diseases by harnessing the power of the human cell through its Shielded Living TherapeuticsTM platform. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.